Location:
ISPO – Cancer Research and Prevention Institute
Clinical and Descriptive Epidemiology Unit
Via delle Oblate 2,
50141, Florence,
Italy
Contact address:
ISPO – Cancer Research and Prevention Institute
Clinical and Descriptive Epidemiology Unit
Via delle Oblate 2, 50141, Florence,
Tel 390557972530
Fax 390557972535
m.zappa@ispo.toscana.it
Local ERSPC protocol foresees:
- randomisation (1:1) of resident males 55-69
- invitation of subjects allocated to active screening arm (call recall by mail)
- PSA (tandem R – Hybritech) determination
- PSA <2.5 ng/ml: return to screening after 4 years
- PSA 2.5-3.9: DRE + TRUS and directed biopsy to DRE/TRUS abnormalities
- PSA 4 > : DRE, TRUS, and routine random sextant biopsy (transperineal US guidied) + directed biopsy to DRE/TRUS abnormalities
- screening started in October 1996: a total of 15,000 subjects have been randomised up to October 2000 when second round started
- local focus of interest
- selection criteria for biopsy, to improve its positive predictive value
- determination of opportunistic PSA in the control arm
- estimate and determination of overdiagnosis magnitude